There are many new intraocular injectable treatments available at Ohio Eye Alliance. An intraocular injection allows medication to be absorbed directly into the eye, maximizing its effectiveness.
In each injection, the eye is numbed, either through topical anesthetsiaor with a small dose of anesthetic injected under the conjunctiva, the surface layer of the eye. Aseptic techniques are always employed to minimize any risk of infection. After treatment, patients are given a prescription for topical antibiotic eye drops as well.
After injection, it is common for patients to experience “floaters” in their vision, as the medication moves inside the eye. This gradually lessens and resolves as the medication is absorbed into the eye. This process takes 2-3 days.
Avastin was originally developed as a treatment for metastatic colorectal cancer. Avastin works by inhibiting the vascular endothelial growth factor (VEGF) to cease blood vessel formation in tumors.
Ophthalmologists are using Avastin “off-label” to treat AMD and similar conditions since research indicates that VEGF is one of the causes for the growth of the abnormal vessels that cause these conditions. Some patients treated with Avastin had less fluid and more normal-appearing maculas, and their vision improved. Avastin is also used, therefore, to treat macular edema, or swelling of the macula.
Visudyne, Macugen and Lucentis
Other forms of treatment are available. At present, there are three FDA-approved treatments for neovascular age-related macular degeneration: photodynamic therapy with a drug called Visudyne™ and injection into the eye of two other VEGF inhibitors drugs called Macugen™ and Lucentis™. Although both of these treatments have been proven to slow down the rate of visual loss, most people do not get back better vision.
All of these treatments are available through Ohio Eye Alliance. New treatments are currently in development and give hope for patients at risk for vision loss. Dr. Garfinkle continues to provide the best and most advanced treatments available for his patients, and looks forward to offering expanded treatment options.
Triesence is an intravitreal steroid injection, recently approved for use by Medicare. Intravitreal steroids can be helpful when other options are unsuccessful. This can be especially helpful in cases of diabetic macular edema and uveitis.
Triesence is also approved for treatment of sympathetic ophthalmia, temporal arteritis, and ocular inflammatory conditions unresponsive to topical corticosteroids.